

Organization Disclosures



[Click here to view individual disclosures](#)

Accelerated Cure

2009

Events - \$300,019

Individual Giving - \$698,523

Pharmaceutical Support - \$124,125 (individual support listed as follows)

Biogen Idec - \$60,000

EMD Serono - \$40,000

Genentech - \$10,050

Teva Neuroscience - \$10,000

Pfizer - \$4,075

Other Corporate/Foundation Support - \$3,910,191

Total - \$5,032,858

American Academy of Neurology

2010

Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology, American Academy of Neurology Institute, American Academy of Neurology Foundation, AAN Enterprises, Inc.). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).

2010 Industry Contribution

Main Menu

[Home](#)

[Disclosures](#)

[Organization Disclosures](#)

[Individual Disclosures](#)

[Medications](#)

[Disease Modifying](#)

[Alemtuzumab \(Lemtrada\)](#)

[Dimethyl Fumarate \[formerly called BG-12\] \(Tecfidera\)](#)

[Fingolimod \(Gilenya\)](#)

[Pegylated Interferon Beta-1A \(Plegridy\)](#)

[Teriflunomide \(Aubagio\)](#)

[Symptom Management](#)


[Dalfampridine \(Ampyra\)](#)

[Dextromethorphan hydrobromide/Quinidine sulfate \(Nuedexta\)](#)

[OnabotulinumtoxinA \(Botox\)](#)

[Updated Information on Approved Treatments](#)

[Tools and Resources](#)



Educational Grants: \$857,416
 Sponsorship: \$1,027,800
 Charitable Contributions (Foundation): \$83,000
 Corporate Roundtable Membership Dues (Foundation): \$690,000
 Exhibit Space: \$2,053,500
 Advertising: \$771,053
 Companies Contributing over \$100,000 in 2010:
 Biogen Idec
 TEVA Neuroscience, Inc.
 Pfizer Inc.
 Allergan, Inc.
 EMD Serono, Inc.
 UCB, Inc.
 Acorda Therapeutics, Inc.
 Novartis Pharmaceuticals
 Bayer HealthCare Pharmaceuticals
 Lilly USA, LLC
 Sunovion Pharmaceuticals Inc. (formerly Sepracor)
 Merz Pharmaceuticals, LLC
 Forest Pharmaceuticals, Inc.
 Lundbeck Inc.

*Based on forecasted amounts. 2010 audit not yet complete.

2009

Below is a breakdown of industry contribution towards the consolidated revenue of the Academy (American Academy of Neurology, American Academy of Neurology Institute, American Academy of Neurology Foundation, AAN Enterprises, Inc.). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the healthcare sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).

2009 Industry Contribution

Total Industry-related Revenue: \$5,538,907
 Percentage of Total Academy Revenue: 18%
 Educational Grants: \$944,483

**PROTOCOL FOR INCLUSION
 OF TREATMENTS
 ON THIS SITE**

As therapies are approved for use in MS, they are reviewed by members of the Collaborative for possible inclusion on this site. All site content is created at the discretion of Collaborative members.

For more information, please email us at emergingtherapies@ms-coalition.org

Charitable Contributions (Foundation): \$ -

Corporate Roundtable Membership Dues (Foundation):
\$450,000

Exhibit Space: \$2,426,700

Advertising: \$486,494

Companies Contributing over \$100,000 in 2009:

Biogen Idec

TEVA Neuroscience, Inc.

UCB, Inc.

Allergan, Inc.

Pfizer Inc.

Bayer HealthCare Pharmaceuticals

Acorda Therapeutics, Inc.

EMD Serono, Inc.

Lilly USA, LLC

Lundbeck Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Ortho-McNeil Neurologics, Inc.

Cephalon, Inc.

Forest Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc.

Merck

Americas Committee for Treatment and Research in Multiple Sclerosis

ACTRIMS is a community of leaders dedicated to treatment and research in multiple sclerosis, dissemination of knowledge and education, and collaboration among disciplines. It also seeks to foster clinical and research talent among young researchers. ACTRIMS is dedicated to providing leadership in the field of multiple sclerosis and other demyelinating diseases.

ACTRIMS is a board-directed, non-membership organization. Founded in 1995 ACTRIMS was formally incorporated in 2009 and was recognized by the IRS as a tax exempt organization under section 501(c)(3) of the Internal Revenue Code. The present principle activity of ACTRIMS is to provide an annual educational meeting for the presentation, discussion and debate of current topics in MS clinical and basic research. Participants include clinicians, clinical scientists, and basic researchers. In select years since 1999, ACTRIMS has held joint meetings with its European counterpart, ECTRIMS. Sources of revenue include registration fees, sponsorship, exhibit hall fees and

2010

ACTRIMS received educational grants in support of its annual meeting. Contributors included the following:

Advir - \$5,000

Genzyme - \$5,000

Society of Canada - \$14,625

Teva Neuroscience - \$25,000

Can Do Multiple Sclerosis

Can Do Multiple Sclerosis is an innovative provider of lifestyle empowerment programs for people with MS and their support partners who want to overcome the challenges of their disease and learn what is possible with MS. Can Do MS **envisions a world in which all people impacted by MS maximize their potential, improving their quality of life.** It is our mission to lead the way with comprehensive programs that empower people and families living with MS to transform and improve their quality of life. Achieving our vision requires a diverse base of support. Our sources of support include the following:

Pharmaceutical Support: Pharmaceutical companies provide financial support for our lifestyle empowerment programs and patient and professional education. Total pharmaceutical support is 48% (\$727,076 in 2013) of our total annual revenue.

Individual Giving: Generous individual donors also provide funding for our lifestyle empowerment programs. Donations at all giving levels contribute approximately 27% (\$412,461 in 2013) to our annual revenue.

Foundation Support: Foundation support is 17% (\$255,275 in 2013) of our annual revenue. Many local and national foundations also support our programs and assist in our bringing them to various areas around the country.

Corporate support of approximately 10% (\$152,178 in 2013) added to our total revenue. Corporations across the country support our mission through direct financial support, cause-related partnerships, and in-kind goods and services.

Special Events: Can Do MS benefits from special events held throughout the year which raise funds needed to support our mission. The major fundraising events in 2013 were the Vertical Express for Can Do MS event series (at Crystal Mountain, WA; Schweitzer Mountain, ID; and Squaw Valley, CA), the Alpen Wine Festival (Squaw Valley, CA), the Cut N Slice Golf Tournament (Beaver Creek, CO), Can Do Day (Eagle County,

Additionally, Can Do MS benefits from events conducted by supporters of our mission all over the country. These events include an endurance run, fundraising dinners, a golf event, among others. Approximately 41% (\$621,700) of the total 2013 revenue of Can Do MS was raised by special events.

Consortium of Multiple Sclerosis Centers

2010

The Consortium of Multiple Sclerosis Centers is the grateful recipient of grants and other support from: Acorda Therapeutics, Inc., Allergan, Inc., Bayer HealthCare Pharmaceuticals, Inc., BiogenIdec, EMD Serono, Novartis Pharmaceuticals, Inc., and TEVA Pharmaceuticals U.S.A.

International Organization of Multiple Sclerosis Nurses

2010

The International Organization of Multiple Sclerosis Nurses is the grateful recipient of grants and other support from: Acorda Therapeutics, Inc., Bayer HealthCare Pharmaceuticals, Inc., BiogenIdec and TEVA Pharmaceuticals U.S.A.

Multiple Sclerosis Association of America

2013

Pharmaceutical Industry Supporters:

Acorda Therapeutics Inc.	\$139,300
Allergan, Inc.	\$111,489
Bayer Healthcare Pharmaceuticals	\$60,940
Biogen Idec	\$234,614
EMD Serono, Inc. and Pfizer, Inc.	\$449,820
Genentech, Inc.	\$15,000
Genzyme	\$395,426
Medtronic Foundation	\$45,500
Novartis Pharmaceuticals Corporation	\$330,495
Questcor Pharmaceuticals, Inc.	\$340,740
Teva Pharmaceuticals	\$384,046

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.